D-0082-2018 Class III Terminated

Recalled by Jubilant Cadista Pharmaceuticals, Inc. — Salisbury, MD

FDA drug recall D-0082-2018 was initiated by Jubilant Cadista Pharmaceuticals, Inc. on Oct 30, 2017 and is designated Class III. Reason for recall: Marketed without an approved NDA/ANDA: Bottles were released prior to final approval. The recall status is terminated (terminated Feb 12, 2020). Affected quantity: 744 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 22, 2017
Initiation Date
Oct 30, 2017
Termination Date
Feb 12, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
744 bottles

Product description

Meclizine hydrochloride tablets USP, 12.5 mg, 100 count HDPE bottle, Rx only, Manufactured by: Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 21801, NDC 59746-122-06

Reason for recall

Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.

Distribution pattern

Nationwide

Code information

Lot # 17P0430, Exp 05/19

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0082-2018
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0082-2018. Report a data issue: hello@regdatalab.com.